Rio de Janeiro, Brazil

Gisele Zapata Sudo


Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gisele Zapata Sudo: Innovator in Cardiac Treatment

Introduction

Gisele Zapata Sudo is a prominent inventor based in Rio de Janeiro, Brazil. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with therapeutic properties. Her work focuses on innovative solutions for treating cardiac conditions.

Latest Patents

Gisele holds a patent for a compound known as Thienylhydrazon, which exhibits digitalis-like properties. This invention, characterized by its formula, includes various groups such as hydrogen, alkyl chains, and phenyl derivatives. The compound is noted for its positive inotropic effects, making it beneficial for cardiac and skeletal muscle treatment. Specifically, it is useful in addressing congestive heart failure and muscle fatigue, while lacking the toxic effects commonly associated with digitalis glycosides.

Career Highlights

Gisele Zapata Sudo is affiliated with the University System of Maryland, where she continues her research and development efforts. Her innovative approach has led to the synthesis of 3,4-methylenedioxybenzoyl-2-thienylhydrazone, also known as LASSBio-294. This compound has shown promising results in enhancing cardiac function.

Collaborations

Gisele has collaborated with notable colleagues, including Roberto Takashi Sudo and Edson X Albuquerque. Their combined expertise has contributed to the advancement of her research and the successful development of her patented compounds.

Conclusion

Gisele Zapata Sudo is a trailblazer in the field of cardiac treatment innovations. Her work not only showcases her inventive spirit but also holds the potential to improve the quality of life for individuals suffering from heart-related ailments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…